Jun Miyata
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (21)
Year:
2026
One of the challenges in diagnosing psychiatric disorders is that the results of biological and neuroscience research are not reflected in the diagnostic criteria. Thus, data‐driven analyses incorporating biological and cross‐disease perspectives, regardless of the diagnostic category, have recently been proposed. A data‐driven clustering study based on subcortical volumes in 5604 subjects classified into four brain biotypes associated with cognitive/social functioning. Among the four brain biotypes identified in controls and patients with schizophrenia, bipolar disorder, major depressive disorder, autism spectrum disorder, and other psychiatric disorders, we further analyzed the brain biotype 1 subjects, those with an extremely small limbic region, for clinical utility. We found that the representative feature of brain biotype 1 is enlarged lateral ventricles. An enlarged ventricle, defined by an average z ‐score of left and right lateral ventricle volumes > 3, had a sensitivity of 99.1% and a specificity of 98.1% for discriminating brain biotype 1. However, the presence of an enlarged ventricle was not sufficient to classify patient subgroups, as 1% of the controls also had enlarged ventricles. Reclassification of patients with enlarged ventricles according to cognitive impairment resulted in a stratified subgroup that included patients with a high proportion of schizophrenia diagnoses, electroencephalography abnormalities, and rare pathological genetic copy number variations. Data‐driven clustering analysis of neuroimaging data revealed subgroups with enlarged ventricles and cognitive impairment. This subgroup could be a new diagnostic candidate for psychiatric disorders. This concept and strategy may be useful for identifying biologically defined psychiatric disorders in the future.
Year:
2025
Electroconvulsive therapy (ECT) is one of the most effective treatments for depression. ECT induces volume changes in the amygdala, a key center of anxiety. However, the clinical relevance of ECT-induced changes in amygdala volume remains uncertain. We hypothesized that nuclei-specific amygdala volumes and anxiety symptoms in depression could explain the clinical correlates of ECT-induced volume changes. To test this hypothesis, we enrolled patients with depression who underwent ECT (N = 20) in this multicenter observational study and collected MRI data at three time points: before and after treatment and a 6-month follow-up. Patients who received medication (N = 52), cognitive behavioral therapy (N = 63), or transcranial magnetic stimulation (N = 20), and healthy participants (N = 147) were included for comparison. Amygdala nuclei were identified using FreeSurfer and clustered into three subdivisions to enhance reliability and interpretability. Anxiety symptoms were quantified using the anxiety factor scores derived from the Hamilton Depression Rating Scale. Before treatment, basolateral and basomedial subdivisions of the right amygdala were smaller than those of healthy controls. The volumes of the amygdala subdivisions increased after ECT and decreased during the follow-up period, but the volumes at 6-month follow-up were larger than those observed before treatment. These volume changes were specific to ECT. Long-term volume changes in the right basomedial amygdala correlated with improvements in anxiety symptoms. Baseline volumes in the right basolateral amygdala correlated with long-term improvements in anxiety symptoms. These findings demonstrate that clinical correlates of ECT-induced amygdala volume changes are existent, but in a nucleus and symptom-specific manner.
Year:
2025
Year:
2025
Year:
2025
Aim Cognitive impairment in schizophrenia shows limited improvement with pharmacotherapy, indicating a need for effective treatment. The frontoparietal network supports working memory, and a biomarker has successfully predicted performance in patients, with the left frontoparietal network contributing the most to working memory. We hypothesized that enhancing functional connectivity in this network through real‐time neurofeedback (NF) will improve working memory in patients with schizophrenia. Methods We conducted a two‐arm, nonrandomized pilot study in patients with schizophrenia, with a NF group ( N = 11) and a control N‐back training group ( N = 11). The NF training lasted 5 days (one session per day). The first session included baseline measurements, while the next four sessions involved training. The participants completed cognitive and clinical assessments and resting‐state scans preintervention and postintervention. Our primary neural outcome was increased functional connectivity during NF, and the behavioral outcome was improvement in working memory, as indicated by scores on the digit‐span backward task and working memory capability measured by the N‐back task. Results The NF group showed increased functional connectivity within the left frontoparietal network during the final session. A significant correlation existed between functional connectivity and the improvement in the mean N‐back level, indicating that enhancing this network can boost working memory. A group‐by‐time interaction effect improved postintervention task score on the digit‐span backward task in the NF group. In addition, post‐NF scans indicated an enhanced resting‐state functional connectivity within the left frontoparietal network. Conclusion These results highlight the potential of functional connectivity–informed NF as a novel therapeutic approach for improving working memory in schizophrenia. Clinical Trial Registration Japan Registry of Clinical Trials (UMIN000024831, jRCTs052180168, jRCTs032190244).
Year:
2025
Year:
2025
Computational saliency map models have facilitated quantitative investigations into how bottom-up visual salience influences attention. Two primary approaches to modeling salience computation exist: one focuses on functional approximation, while the other explores neurobiological implementation. The former provides sufficient performance for applying saliency map models to eye-movement data analysis, whereas the latter offers hypotheses on how neuronal abnormalities affect visual salience. In this study, we propose a novel saliency map model that integrates both approaches. It handles diverse image-derived features, as seen in functional approximation models, while implementing center-surround competition—the core process of salience computation—via an artificial neural network, akin to neurobiological models. We evaluated our model using an open eye-movement dataset and confirmed that its predictive performance is comparable to the conventional saliency map model used in eye-movement analysis. Beyond eye-movement prediction, our model enables neural-level simulations of how neurobiological disturbances influence salience computation. Simulations showed that parameter changes for excitatory-inhibitory balance, baseline neural activity, and synaptic connection density affected the contrast between salient and non-salient objects—in other words—the weighting of salience. Finally, we demonstrated the model’s potential for quantifying changes in salience weighting as reflected in eye movements, highlighting its ability to bridge both predictive and neurobiological perspectives. These results present a novel strategy for investigating mechanisms underlying abnormal visual salience.
Year:
2025
Background Methamphetamine-induced psychosis (MIP) is characterized by transient episodes, but a substantial portion persists long-term (Wearne &Cornish 2018). While symptom similarities exist between MIP and schizophrenia (Sz), their neural correlates remain uncertain. Furthermore, research into the neural basis underlying the presence and duration of MIP psychosis has been limited. Aims & Objectives This study aimed to investigate whether there would be differences in discriminatory ability when classifying methamphetamine (METH) users with or without psychosis and Sz using Sz classifier derived from resting-state fMRI. We also aimed to explore potential differences in the presence and duration of psychosis in METH users. Method Utilizing the machine learning algorithms (Yamashita et al. 2020), we constructed an Sz classifier using whole-brain functional connectivity from resting-state fMRI data sourced from a Japanese database with 78 Sz patients and 340 healthy individuals (Tanaka et al. 2021). The classifier was tested using independent datasets. For the Taiwan dataset, which consisted of 35 Sz patients, 106 regular METH users and 45 healthy individuals, we applied this classifier to differentiate fMRI data of Sz patients and METH users from healthy individuals. METH users were grouped as MNP (no psychosis, 30 participants), MBP (psychosis lasting 7-30 days, 52 participants), and MPP (psychosis >30 days, 24 participants). Discriminatory abilities of these groups were then compared. Results The Sz classifier's performance ranged from an AUC of 0.77 to 0.86, indicating reliable discriminatory performance. In the Taiwan dataset, Sz exhibited the highest AUC (0.90), followed closely by MPP (AUC: 0.82). Both MBP and MNP displayed values around 0.6. These patterns were consistent in accuracy. Discussion & Conclusion Both Sz and MPP demonstrated high discriminatory capacities, in contrast to MBP and MNP, which showed less distinction. This suggests that persistent MIP shares neurobiological characteristics more similar to Sz, while transient MIP shares more similar to METH users without psychosis and healthy individuals. The slight differences in performance between Sz and MPP might shed light on their respective pathophysiology. Our method provides a framework for categorizing METH users by their psychosis manifestation and duration, highlighting shared and distinct neurobiological aspects of MIP and Sz. References Wearne, T. A., &Cornish, J. L. (2018). A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology. Frontiers in psychiatry, 9, 491. Yamashita, A., Sakai, Y., Yamada, T., Yahata, N., Kunimatsu, A., Okada, N., Itahashi, T., Hashimoto, R., Mizuta, H., Ichikawa, N., Takamura, M., Okada, G., Yamagata, H., Harada, K., Matsuo, K., Tanaka, S. C., Kawato, M., Kasai, K., Kato, N., Takahashi, H. &Imamizu, H. (2020). Generalizable brain network markers of major depressive disorder across multiple imaging sites. PLoS biology, 18(12), e3000966. Tanaka, S. C., Yamashita, A., Yahata, N., Itahashi, T., Lisi, G., Yamada, T., Ichikawa, N., Takamura, M., Yoshihara, Y., Kunimatsu, A., Okada, N., Hashimoto, R., Okada, G., Sakai, Y., Morimoto, J., Narumoto, J., Shimada, Y., Mano, H., Yoshida, W., Seymour, B. &Imamizu, H. (2021). A multi-site, multi-disorder resting- state magnetic resonance image database. Scientific data, 8(1), 227.
Year:
2025
Background The creation of a novel diagnostic system using objective biomarkers is expected to take place, due to difficulty of the current diagnostic system based on symptoms in psychiatry. Aims & Objectives We clustered the 5602 subjects based on brain subcortical volumes and showed a four-biotype classification, namely extremely (Brain Biotype [BB] 1: n=110) and moderately smaller limbic regions (BB2: n=566), larger basal ganglia (BB3: n=679), and normal volumes (BB4: n=4247), being associated with cognitive/social functioning (Mol Psychiatry, 2023). In the present study, we performed a detailed examination of the biological and clinical characteristics of these biotypes. Method A total of 5602 patients in the previous paper, including healthy subjects (n=3077), patients with schizophrenia (SZ: n=1499), bipolar disorder (BD: n=234), major depressive disorder (MDD: n=598), autism spectrum disorder (ASD: n=189) and other psychiatric disorders (O: n=5), were included. The biological and clinical characteristics of four biotypes were investigated using subcortical volumes from T1-weighted MRI images, cognitive functions, EEG, and genomic information. Results We examined the differences in subcortical volume characteristics in each biotype and found that the lateral ventricle volume was remarkably larger (Z-score = 5.1 ± 1.8) in BB1 (n=110). 99.1% of BBI subjects had the lateral ventricle volume greater than 3 standard deviation (3 SD) of normal subjects, and this brain feature discriminated BB1 with a sensitivity of 99.1% and a specificity of 98.1%. Therefore, BB1 was redefined as a brain structural feature with a lateral ventricular volume of 3 SD or greater. Of the 186 redefined subjects, 33 patients with detailed cognitive function data were stratified into two groups: 9 patients with moderate or higher cognitive decline (SZ8/ASD1) and 24 patients with mild or lower cognitive decline (SZ9/ HC9/ASD4/ MDD1/O1), and compared. EEG abnormalities (71% in the former group, 0% in the latter), a diagnosis of schizophrenia (89% in the former group, 38% in the latter group), and low intelligence (IQ=67 in the former group, IQ=103 in the latter group) were obviously observed in the former group than in the latter. Furthermore, copy number variation analysis of 7 out of 9 cases in the former group showed a high rate of pathological CNV (22q11.21 deletion, 7q11.23 duplication, and DPP6 deletion) in 3 cases, which is only seen in approximately one out of several thousand normal subjects. Discussion & Conclusion We have identified a novel candidate for classification of psychiatric disorders with high rates of EEG abnormalities, psychotic symptoms, and pathological rare genomic variants in a stratified group of patients with schizophrenia and other psychiatric disorders with lateral ventricular volumes of 3 SD or greater and moderate to severe cognitive decline. We proposed a possible novel psychiatric disorder by going back to each patient based on the clinical significance from a large-scale data-driven analysis screening, and proposed a methodology to find the concept and psychiatric disorders by objective indices for the first time in the world.This new biotype classification suggests that objective measurements based on neuroimaging data will be incorporated into psychiatric diagnosis in the future.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (18)
Hisashi Narita
assistant professor
Hokkaido University Hospital
Masaki Fukunaga
特任教授/Project Professor
生理学研究所/National Institute for Physiological Sciences
Motohiro Okada
Hirosaki University
Hirotsugu Kawashima
Kyoto University Hospital
Koichi Tabata
Assistant Professor
Tokyo Institute of Technology
Kenji Doya
Professor
Okinawa Institute of Science and Technology Graduate University
Daisuke Matsuyoshi
Senior Research Scientist
National Institutes for Quantum and Radiological Science and Technology
Manabu Kubota
Kyoto University
Tom Johnstone
Professor
Swinburne University of Technology
Saori Tanaka
Professor
Nara Institute of Science and Technology(NAIST)
Shisei Tei
Professor
Kyoto University
Nobuhiro Nohara
Assistant Professor
University of Tokyo Hospital
Masanori Isobe
Kyoto University Hospital
Naoya Oishi
准教授 / Associate Professor
Kyoto University
Yoshihisa Fujita
Kyoto University
Tomomi Noda
Kyoto University
Hiroshi Imamizu
Professor
University of Tokyo
Kiyotaka Nemoto
Professor
University of Tsukuba
Make your next move.
Prepare your application
Review drafts before you send them.